This piece is highlighted because of its significance. Please check out the rest of TopMedTalk’s coverage of the conference on our website –

Regular listeners will appreciate the importance of the PeriOperative ISchemic Evaluation-3 Trial (POISE-3). Here we highlight a conversation containing late breaking news on the subject.

The New England Journal of Medicine is here:

Presented by Desiree Chappell and Monty Mythen with their guests Frederic Michard, MD of MiCo Consulting and Daniel Sessler, Michael Cudahy Professor and Chair at Cleveland Clinic, Director of The Outcomes Research Consortium.